---
title: "Pacific Shuanglin Bio-pharmacy Co.,LTD (000403.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/000403.SZ.md"
symbol: "000403.SZ"
name: "Pacific Shuanglin Bio-pharmacy Co.,LTD"
industry: "Biotechnology"
datetime: "2026-05-21T03:11:18.311Z"
locales:
  - [en](https://longbridge.com/en/quote/000403.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/000403.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/000403.SZ.md)
---

# Pacific Shuanglin Bio-pharmacy Co.,LTD (000403.SZ)

## Company Overview

Pacific Shuanglin Bio-pharmacy Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of blood products in China and internationally. The company offers human serum albumin, human immunoglobulin (PH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus immunoglobulin, rabies immunoglobulin, human coagulation factor VIII, human fibrinogen, lyophilized intravenous immunoglobulin (pH4), hepatitis B immunoglobulin (pH4), and human prothrombin complex concentrate, as well as intravenous cytomegalovirus immunoglobulin and intravenous respiratory syncytial virus immunoglobulin. It is also involved in blood acquisition; plasma collection; consulting; trading; investment activities; and technology promotion and application services. The company was formerly known as Southern Shuanglin Bio-pharmacy Co., Ltd.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.plbio.cn](https://www.plbio.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: C (0.51)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 37 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.28% |  |
| Net Profit YoY | -50.43% |  |
| P/B Ratio | 1.27 |  |
| Dividend Ratio | 2.49% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 10301590678.43 |  |
| Revenue | 2605503230.33 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 4.38% | C |
| Profit Margin | 13.58% | B |
| Gross Margin | 34.82% | C |
| Revenue YoY | 0.28% | C |
| Net Profit YoY | -50.43% | D |
| Total Assets YoY | 2.02% | C |
| Net Assets YoY | 1.22% | C |
| Cash Flow Margin | -77.02% | E |
| OCF YoY | 0.28% | C |
| Turnover | 0.28 | D |
| Gearing Ratio | 13.63% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Pacific Shuanglin Bio-pharmacy Co.,LTD",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.28%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-50.43%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.27",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "2.49%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "10301590678.43",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "2605503230.33",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "4.38%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "13.58%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "34.82%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "0.28%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-50.43%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "2.02%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "1.22%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-77.02%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "0.28%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.28",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "13.63%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 28.26 | 10/81 | 25.67 | 24.01 | 22.90 |
| PB | 1.23 | 7/81 | 2.12 | 1.86 | 1.60 |
| PS (TTM) | 3.84 | 7/81 | 6.60 | 6.12 | 5.38 |
| Dividend Yield | 2.56% | 10/81 | 2.39% | 2.14% | 1.97% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | InnoCare Pharma (688428.SH) | B | A | D | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-08T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 10.64 |
| Highest Target | 19.62 |
| Lowest Target | 19.62 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/000403.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/000403.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/000403.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/000403.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**